WHAT YOU NEED TO KNOW IN 60 SECONDS
SGLT-2 inhibitors are now first-line alongside metformin for most newly diagnosed adults with type 2 diabetes — not second-line.
GLP-1 receptor agonists and tirzepatide move earlier in the pathway for three groups: established CVD, early-onset diabetes (diagnosed <40), and obesity. ~810,000 more people become eligible.
Treatment is now personalised by clinical profile (CVD, CKD, heart failure, frailty, obesity, early-onset) rather than a single linear escalation.
For patients with established atherosclerotic CVD: triple therapy from the start (metformin + SGLT-2i + GLP-1 RA). Semaglutide is the preferred GLP-1 RA.
For frail patients: metformin alone remains appropriate. If not tolerated, consider DPP-4 inhibitor over SGLT-2i if frailty increases adverse event risk.
Generic dapagliflozin now available — estimated NHS savings of £560m over two years.
NICE modelling: this shift could prevent ~17,000 deaths over three years.
Equity flag: SGLT-2 inhibitors are under-prescribed to women, older people, and Black patients. Practices should audit access.
Metformin Alone Is No Longer the Default Starting Point
For over a decade, the first move for a newly diagnosed type 2 diabetes patient was metformin monotherapy. Wait, recheck HbA1c, escalate if needed. That sequence was embedded in the muscle memory of every GP consultation.
The February 2026 update to NG28 ends that era. Most newly diagnosed patients will now be offered an SGLT-2 inhibitor alongside metformin from the outset — introduced stepwise (metformin first to confirm tolerability, then the flozin). For those who can’t tolerate metformin, an SGLT-2 inhibitor alone becomes the starting point.
The guidance also recommends that people should be given a slow- release form of Metformin. Many people suffer stomach upsets from the standard release form which can put them off taking their medicine.
The rationale is no longer just about glucose. SGLT-2 inhibitors have been shown to reduce cardiovascular death, heart failure hospitalisations, and CKD progression independently of HbA1c. NICE’s own modelling suggests this shift could prevent around 17,000 deaths over three years.
810,000 More People Become Eligible for GLP-1s and Tirzepatide
GLP-1 receptor agonists were previously reserved for patients who had failed multiple oral agents. The 2026 update brings them into the initial treatment plan for three groups:
Established atherosclerotic CVD: Triple therapy from the start — metformin + SGLT-2i + GLP-1 RA. Subcutaneous semaglutide (up to 1 mg weekly) is the preferred agent.
Diagnosed before age 40: Dual therapy (metformin + SGLT-2i), then consider adding a GLP-1 RA or tirzepatide. This group faces higher lifetime cardiovascular and renal risk.
Living with obesity: Specific combination pathways now available with GLP-1 RAs or tirzepatide.
Frailty Gets Its Own Pathway — Fewer Medicines, Not More
Not everyone is getting more drugs. The update introduces a dedicated frailty pathway: start with metformin alone. If not tolerated, assess whether frailty increases the risk of SGLT-2 inhibitor adverse events (volume depletion, hypotension). If it does, a DPP-4 inhibitor is the safer choice. NICE explicitly recognises that vulnerable patients often do better with simpler regimens.
Generic Dapagliflozin Changes the Maths: £560m in NHS Savings
The clinical evidence for earlier SGLT-2 inhibitor use has existed for years. What unlocked this update was economics. Generic dapagliflozin is now available, and NICE estimates cumulative savings of £560 million across 2025/26 and 2026/27. Mark Samuels of Medicines UK has suggested prescriptions could rise by 230% to cover 2.4 million people — while still saving money.
Women, Older People and Black Patients Are Being Under-Prescribed
NICE analysed nearly 590,000 anonymised records and found SGLT-2 inhibitors are significantly under-prescribed to women, older people, and Black or Black British individuals. The revised guideline includes provisions to monitor treatment access and address these disparities. People in the most deprived areas would particularly benefit from universal access.
For practices, this means the update is not just about changing what you prescribe. It’s about reviewing who is and isn’t receiving these medicines.
Your New-Diagnosis Consultation Now Starts With Two Medicines
The practical implication is straightforward: the standard new-diagnosis conversation changes. Most patients will be offered combination therapy from day one, framed around long-term heart and kidney protection rather than disease severity. Practice protocols, prescribing templates, and consultation structures may all need updating.
GP leaders have flagged that appropriate support will be needed to implement this consistently and safely, given the likely increase in prescribing and monitoring workload.
Also in This Update
Insulin: Pragmatic changes due to product withdrawals and brand shortages. Biosimilar insulins endorsed as cost-effective alternatives.
CGM access expanded: Intermittently scanned continuous glucose monitoring now recommended for more adults on insulin, particularly those with recurrent or severe hypoglycaemia.
Periodontitis: Routine discussion of gum disease risk incorporated into annual diabetes reviews.
Remission: Links added throughout to the NHS Type 2 Diabetes Path to Remission Programme.
Language: ‘Living with overweight’ replaces ‘being overweight’. ‘Healthy living’ replaces ‘lifestyle’.
This article reports on published NICE guidance. It does not constitute medical advice. Always refer to the full guideline and use clinical judgement when making prescribing decisions.
